Mark Lampert, the founder and manager of Biotechnology Value Fund, is bullish on Cytokinetics, Inc. (NASDAQ:CYTK). According to a recent filing with the Securities and Exchange Commission, Lampert has increased his fund’s stake from 1.79 million to 3.28 million shares, which include some 921,100 shares which can be issued upon the exercise of certain warrants. The fund’s current position accounts for 9.98% of the company’s common stock.
In another filing with the SEC, Biotechnology Value Fund has revealed a reduction in its holding of Regado Biosciences Inc (NASDAQ:RGDO) by 1.32 million shares that were disposed of, leaving the fund with 2.33 million shares which account for 9.99% of the company’s common stock.
Cytokinetics, Inc. (NASDAQ:CYTK) has also attracted the attention of Paul Ruddock and Steve Heinz, the managers of Lansdowne Partners. According to the fund’s latest 13F report, it holds 2.02 million shares valued at $13.1 million, the position suffering no changes in the previous quarter. Jim Simmons is also bullish on this stock, having initiated a position during the fourth quarter of 2013. Renaissance Technologies reported the ownership of 335,300 shares worth $2.17 million in its latest 13F filing. Israel Englander, the manager of Millennium Management, has decided to limit his exposure to Cytokinetics and has decreased his fund’s position by 36% to 554,700 shares valued at $3.6 million.
Cytokinetics, Inc. (NASDAQ:CYTK) engages in the research and design of small molecule therapeutics. The stock has a market cap of $326 million and does not pay a dividend. The stock has entered an uptrend at the end of 2013 and has advanced 38% so far this year to a current price of $8.95 per share. For the three months ending December 31, 2014, Cytokinetics posted revenues of $24.35 million and earnings per share of $0.22, up from a loss of $0.48 per share reported for the same period in 2012. Analysts expect the company to register $7.69 million in revenues and a loss per share of $0.35 during the current quarter.
Only two hedge funds that we track have invested in Regado Biosciences Inc (NASDAQ:RGDO), one of them being Wexford Capital run by Charles Davidson. According to the fund’s latest 13F report, during the previous quarter, it has decreased its holding of the stock by 9% to 324,200 shares valued at $1.54 million. Alyeska Investment Group and its manager, Anand Parekh, are actually bullish and have increased their holding by 76% to 116,000 shares reportedly worth $553,000.
A developer of antithrombotic drug systems, Regado Biosciences Inc (NASDAQ:RGDO) has a market cap of $303 million and does not pay a dividend. The stock has been in an uptrend since the start of the year and has advanced 145% to a current price of $12 per share. For the year ending December 31, 2013, the company posted a net loss of $34.4 million, which translated into a loss per share of $4.59.